Mitsubishi UFJ Trust & Banking Corp Has $11.85 Million Holdings in Exelixis, Inc. $EXEL

Mitsubishi UFJ Trust & Banking Corp lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 4.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 270,396 shares of the biotechnology company’s stock after selling 12,345 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.10% of Exelixis worth $11,851,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. TriaGen Wealth Management LLC purchased a new position in shares of Exelixis during the 3rd quarter valued at about $2,024,000. BridgePort Financial Solutions LLC purchased a new position in shares of Exelixis during the 3rd quarter valued at about $517,000. Candriam S.C.A. raised its holdings in shares of Exelixis by 18.4% during the 3rd quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock valued at $28,749,000 after buying an additional 108,367 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Exelixis by 11.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock valued at $172,658,000 after buying an additional 419,596 shares in the last quarter. Finally, Allianz Asset Management GmbH raised its holdings in shares of Exelixis by 153.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock valued at $101,720,000 after buying an additional 1,490,520 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on EXEL shares. Citigroup cut Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Royal Bank Of Canada decreased their price objective on Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a report on Monday, March 2nd. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, Truist Financial upgraded Exelixis to a “strong-buy” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Exelixis has an average rating of “Hold” and a consensus target price of $47.00.

Insider Transactions at Exelixis

In other news, EVP Dana Aftab sold 47,918 shares of Exelixis stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total value of $2,132,351.00. Following the sale, the executive vice president directly owned 616,106 shares in the company, valued at approximately $27,416,717. This trade represents a 7.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 67,814 shares of Exelixis stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total value of $2,951,265.28. Following the completion of the sale, the executive vice president owned 381,908 shares in the company, valued at approximately $16,620,636.16. This represents a 15.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 362,849 shares of company stock worth $15,917,463. Corporate insiders own 2.82% of the company’s stock.

Exelixis Price Performance

EXEL opened at $43.68 on Friday. The stock’s 50 day simple moving average is $43.31 and its 200 day simple moving average is $42.77. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $49.62. The firm has a market cap of $11.10 billion, a price-to-earnings ratio of 15.77, a PEG ratio of 1.00 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. During the same period last year, the company earned $0.55 EPS. Exelixis’s revenue for the quarter was up 5.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Exelixis, Inc. will post 3.07 EPS for the current year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.